• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.

作者信息

Steele M R, Nagel K, Chan A K C

机构信息

Department of Pediatrics, Division of Hematology/Oncology, McMaster University, Hamilton, ON, Canada.

出版信息

Haemophilia. 2014 Jan;20(1):e100-1. doi: 10.1111/hae.12310. Epub 2013 Nov 19.

DOI:10.1111/hae.12310
PMID:24251412
Abstract
摘要

相似文献

1
Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
Haemophilia. 2014 Jan;20(1):e100-1. doi: 10.1111/hae.12310. Epub 2013 Nov 19.
2
Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.蔗糖配方重组凝血因子VIII对台湾甲型血友病患者的疗效与安全性评估
Haemophilia. 2009 Jul;15(4):968-70. doi: 10.1111/j.1365-2516.2009.02024.x. Epub 2009 Apr 20.
3
Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.在接受手术的重度血友病患者中，持续输注蔗糖配方重组因子 VIII（rFVIII-FS）的稳定性、疗效和安全性。
Haemophilia. 2009 May;15(3):676-85. doi: 10.1111/j.1365-2516.2008.01978.x. Epub 2009 Feb 27.
4
Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.接受蔗糖配方重组凝血因子VIII治疗的甲型血友病患者抑制剂形成的累积分析。
Haemophilia. 2009 Mar;15(2):597-600. doi: 10.1111/j.1365-2516.2008.01938.x. Epub 2009 Feb 1.
5
Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.一项大型多国临床试验（guardian™3）的结果，该试验使用预防性治疗药物 turoctocog alfa 治疗重症甲型血友病儿童患者：安全性、疗效和药代动力学。
Haemophilia. 2013 Sep;19(5):698-705. doi: 10.1111/hae.12165. Epub 2013 May 8.
6
Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.回顾性分析血友病 A 患者每年第八因子利用情况的差异。
Haemophilia. 2012 Mar;18(2):187-92. doi: 10.1111/j.1365-2516.2011.02636.x. Epub 2011 Aug 24.
7
Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A.持续输注长效凝血因子VIII（重组凝血因子VIII）用于重度甲型血友病患者的手术治疗。
Haemophilia. 2018 Jul;24(4):e280-e283. doi: 10.1111/hae.13557. Epub 2018 Jul 25.
8
A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Haemophilia. 2008 Mar;14(2):281-6. doi: 10.1111/j.1365-2516.2007.01634.x. Epub 2008 Jan 8.
9
Prophylaxis in children with haemophilia - the Polish experience.血友病患儿的预防——波兰的经验
Haemophilia. 2014 Jan;20(1):e108-10. doi: 10.1111/hae.12327. Epub 2013 Nov 20.
10
Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.重组人凝血因子Ⅷ（AF-CC）治疗方案对重度甲型血友病患儿出血率的影响。
Haemophilia. 2020 Sep;26(5):e232-e235. doi: 10.1111/hae.14047. Epub 2020 Jun 4.

引用本文的文献

1
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.意大利重组凝血因子VIII浓缩物治疗甲型血友病的现状：特点与临床益处
Front Med (Lausanne). 2019 Dec 3;6:261. doi: 10.3389/fmed.2019.00261. eCollection 2019.